Why macrophage-targeted nanomedicine keeps stalling before trials

A 2026 field review in Frontiers in Immunology argues that getting the drug to the right cell, not choosing the right target, is the real bottleneck in macrophage-targeted nanomedicine. Macrophages are innate immune cells that can either suppress tumors or help them grow, and either stabilize arterial plaque or rupture it; their behavior shifts with the local inflammatory and metabolic signals around them. That plasticity is the biological opportunity and the engineering headache.

The Huang et al. review maps a decade of work around a two-step delivery idea: nanoparticles decorated so that scavenger receptors, surface proteins enriched on disease-associated macrophages, pull them inside, then an enzyme those same macrophages overproduce, cathepsin B, breaks the carrier open and frees the cargo. STAT3, the intracellular signal the authors single out, stabilizes the pathological macrophage state the therapy is trying to reverse; the review is careful to call it a translationally relevant node rather than the exclusive axis.

The authors also name three failure modes the field keeps hitting: off-target sequestration by non-diseased macrophages, patient-to-patient heterogeneity in which scavenger receptors actually dominate, and whether enough intact drug reaches the right cell to matter. Those three problems apply in tumor tissue and in atherosclerotic plaque, which is why the same delivery platform is now being tested across both diseases. A PubMed listing carries the same record.

The paper is a synthesis, not a clinical readout. Authors Huang, Cai, Yan, Tong, and Li declared no commercial conflicts.